Preventative approach could reduce immunotherapy side effects
European Pharmaceutical Review
JANUARY 4, 2024
Immunotherapy drugs like teclistamab can result in potentially fatal side effects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS). In 2022, the drug was approved by the US Food and Drug Administration (FDA) for these patients. We are going with full steam into an era of immunotherapy.”
Let's personalize your content